March 1, 2025 - 01:52

Chris Robinson, MD, PhD, recently emphasized the critical role of patient education in the evolving landscape of pain management technologies. As advancements in treatment options emerge, it is essential for patients to be well-informed about these innovations to make educated decisions regarding their health.
Robinson highlighted that many patients may feel overwhelmed by the rapid pace of technological development in pain management. This can lead to confusion and hesitation when considering new treatment options. By providing comprehensive education on these technologies, healthcare providers can empower patients to engage actively in their treatment plans.
Moreover, understanding these emerging technologies can help patients weigh the benefits and potential risks associated with different pain management strategies. Robinson advocates for a collaborative approach, where healthcare professionals and patients work together to navigate the complexities of new treatments. Ultimately, fostering a well-informed patient base is crucial for improving outcomes and enhancing the overall experience in pain management.
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...